<DOC>
	<DOCNO>NCT02751138</DOCNO>
	<brief_summary>Glioblastoma multiforme ( GBM ) common primary brain tumor adult . Despite intensive research effort multimodal management actually consist surgery , radiotherapy chemotherapy temozolomide , prognosis dismal . The aim current observational study determine immune phenotype individual patient GBM time diagnosis correlate tumor size , location ( image ) , tumor property ( isocitrate dehydrogenase - 1 ( IDH-1 ) , o6-methylguanine-DNA-methyltransferase ( MGMT ) , epidermal growth factor receptor ( EGFR ) mutation status , etc . ) clinical data , progression free overall survival , Karnofsky index ( progression free survival ( PFS ) , overall survival ( OS ) , Karnofsky score ( KFS ) ) , blood immune phenotype , biomarkers , immune histochemical result tumor infiltrate lymphocyte , macrophage , myeloid derive suppressor cell ( MDSC ) , etc.. The different immunological phenotype could predict positive response specific immunological therapeutic strategy select individual therapeutic plan individual GBM patient .</brief_summary>
	<brief_title>Determination Immune Phenotype Glioblastoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>adult glioblastoma multiforme pregnancy , unable give consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Immune phenotype</keyword>
	<keyword>Cytokines</keyword>
	<keyword>Genetic aberration</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Progression free survival</keyword>
</DOC>